靶向PD-L1与PD-L2的双特异性抗体124I标记探针的构建及临床前评价
本研究构建了由两个抗PD-L1纳米抗体和两个抗PD-L2纳米抗体组成的双特异性抗体NB12,并在室温下用放射性核素124I进行标记,得到[124I]I-NB12。体外结合实验、细胞摄取、药代动力学、生物分布及micro-PET/CT显像等临床前评价显示,[124I]I-NB12对PD-L1和PD-L2具有亲和力,micro-PET/CT证实了在体内可视化肿瘤PD-L1/2的可行性。
要点
- 双特异性抗体NB12由两个抗PD-L1纳米抗体和两个抗PD-L2纳米抗体组成。
- [124I]I-NB12对PD-L1的Kd为19.82 nM,对PD-L2的Kd为2.93 nM。
- 注射后24 h,A549-PDL1/2荷瘤小鼠肿瘤区摄取高于A549荷瘤小鼠。
核心结论
- 作者构建了靶向PD-L1和PD-L2的双特异性抗体[124I]I-NB12,生物学评价显示其对PD-L1/2具有特异性和亲和力,micro-PET/CT证实了在体内可视化肿瘤PD-L1/2的可行性。
- 作者认为使用[124I]I-NB12可能是一种有前景的策略,用于识别可能从ICI治疗中获益的癌症患者。
研究设计与样本
- 本研究为临床前研究,构建了由两个抗PD-L1纳米抗体和两个抗PD-L2纳米抗体组成的双特异性抗体NB12,并在室温下用放射性核素124I标记。
- 进行了体外结合实验、细胞摄取、药代动力学和生物分布实验,并在不同时间点进行micro-PET/CT显像,同时用免疫组化和HE染色、常规血液、生化指标及主要器官病理评价生物安全性。
主要发现
- [124I]I-NB12的放射化学产率为84.62 ± 3.90%,放射化学纯度大于99%。
- [124I]I-NB12对PD-L1的Kd为19.82 nM,对PD-L2的Kd为2.93 nM。
- 细胞摄取实验证实A549-PDL1/2细胞对[124I]I-NB12的摄取高于A549细胞。
- 分布相和消除相的半衰期分别为0.26 h和4.08 h。
- micro-PET/CT显示注射后24 h,A549-PDL1/2荷瘤小鼠肿瘤区[124I]I-NB12摄取明显高于A549荷瘤小鼠。
关键数值与推荐
- [124I]I-NB12的放射化学产率为84.62 ± 3.90%,放射化学纯度大于99%。
- [124I]I-NB12对PD-L1的Kd为19.82 nM,对PD-L2的Kd为2.93 nM。
- 分布相半衰期为0.26 h,消除相半衰期为4.08 h。
临床怎么用
- 作者认为使用[124I]I-NB12可能是一种有前景的策略,用于识别可能从ICI治疗中获益的癌症患者。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: NB12 is a bispecific antibody that consists of two anti-programmed cell death-ligand 1 (PD-L1) nanobodies and two anti-programmed cell death-ligand 2 (PD-L2) nanobodies. The aim of this study was to design a novel tracer, [124I]I-NB12, targeting PD-L1/2 and perform preclinical evaluations to dynamically monitor PD-L1/2 expression for determining cancer patient responsiveness to ICI therapy. METHODS: NB12 was labelled with the radionuclide 124I at room temperature (RT). An in vitro binding assay was performed to assess the affinity of [124I]I-NB12 for PD-L1 and PD-L2. Cellular uptake, pharmacokinetic, and biodistribution experiments were performed to evaluate the biological properties. Micro-PET/CT imaging with [124I]I-NB12 was conducted at different time points. Immunohistochemical and haematoxylin and eosin (HE) staining experiments were carried out using tumour tissues. Routine blood, biochemical indices and major organ pathology were used to evaluate the biosafety of the tracers. RESULTS: The radiochemical yield of [124I]I-NB12 was 84.62 ± 3.90%, and the radiochemical purity (RCP) was greater than 99%. [124I]I-NB12 had a high affinity for the PD-L1 (Kd = 19.82 nM) and PD-L2 (Kd = 2.93 nM). Cellular uptake experiments confirmed that the uptake of [124I]I-NB12 by A549-PDL1/2 cells was greater than that by A549 cells. The half-lives of the distribution phase and elimination phase were 0.26 h and 4.08 h, respectively. Micro-PET/CT showed significant [124I]I-NB12 uptake in the tumour region of A549-PDL1/2 tumour-bearing mice compared with A549 tumour-bearing mice 24 h postinjection. Immunohistochemical and HE staining experiments confirmed that tumour-bearing mice was successfully constructed. CONCLUSION: We constructed a bispecific antibody that targets PD-L1 and PD-L2, namely, [124I]I-NB12. Biological evaluation revealed its specificity and affinity for PD-L1/2, and micro-PET/CT confirmed the feasibility of visualizing tumour PD-L1/2 in vivo. Using [124I]I-NB12 may be a promising strategy for identifying cancer patients that can potentially benefit from ICI therapy.
引用
- Yao Y, Ren Y, Hou X, et al. Construction and preclinical evaluation of a 124I-labelled bispecific antibody targeting PD-L1 and PD-L2. Eur J Nucl Med Mol Imaging. 2024. PMID: 39155310. doi:10.1007/s00259-024-06886-5
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。